ClinicalTrials.gg
Enrolling by invitationNCT07591610Periop HFNOUpdated Nov 19, 2026

Perioperative High-flow Nasal Oxygen in Patients Undergoing Robotic Surgery

An interventional study of High flow nasal oxygen in Robotic Surgery, sponsored by Beth Israel Deaconess Medical Center. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Now Enrolling by invitationStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to assess whether perioperative use of high-flow nasal oxygen (HFNO) during the period from induction of anesthesia until discharge from the post-anesthesia care unit in patients undergoing robotic-assisted surgery reduces perioperative oxygen desaturation, atelectasis formation and postoperative pulmonary complications.

Read the detailed description

The investigators hypothesize that perioperative HFNO reduces perioperative oxygen desaturation, atelectasis formation and postoperative pulmonary complications in patients undergoing robotic-assisted surgery.

02

Conditions studied

  • Robotic Surgery

Keywords

  • Electric Impedance Tomography (EIT)
  • High-flow nasal oxygenation
  • Perioperative oxygenation
  • Robotic surgery
03

In context

Lead sponsor

Beth Israel Deaconess Medical Center is the lead sponsor of 570 studies on the registry; 80 are open to participants now.

Of its 76 completed or terminated interventional studies of FDA-regulated products, 62 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18
  • Undergoing non-emergent, non-cardiac, intra-abdominal, intra-thoracic or pelvic robot-assisted surgery with an expected duration of at least 2 hours under general anesthesia with planned extubation at the end of the procedure

Exclusion criteria

Exclusion Criteria:

  • Known pregnancy
  • Preoperative intubation or tracheostomy
  • Anatomical or clinical conditions precluding the use of high-flow nasal oxygen (severe midface trauma, recent nasal surgery, severe nasal septum deviation, severe nasal deformation)
  • to electrical impedance tomography (EIT), including inability to place the EIT belt or presence of active implantable electronic devices (e.g., pacemaker or implantable cardioverter-defibrillator)
  • Planned postoperative admission to the intensive care unit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
190 participants (estimated)

Study arms

  • No intervention
    Control

    In the control group, patients will receive standard of care anesthesia treatment, consisting of conventional preoxygenation and no active oxygen delivery during the apneic phase of induction. Following extubation, supplemental oxygen will be administered via face mask and subsequently weaned to standard nasal cannula as per routine clinical practice.

  • Experimental
    Intervention

    In the intervention group, patients will receive high-flow nasal oxygen starting from induction of anesthesia until intubation, and from extubation until discharge from PACU with weaning of high-flow nasal oxygen during their PACU stay.

    Device: High flow nasal oxygen

Interventions

  • DeviceHigh flow nasal oxygen

    In the intervention group, high-flow nasal oxygen (HFNO) will be initiated at the start of preoxygenation and maintained throughout the apneic phase of induction until successful tracheal intubation. HFNO will be reinitiated immediately prior to extubation and continued throughout the early postoperative period until discharge from the post-anesthesia care unit (PACU). HFNO can be discontinued earlier in the PACU at the discretion of the nurse treating the patient, or upon patient request. HFNO can further be changed to standard of care (standard oxygen mask or standard nasal cannula) at any time at the discretion of the anesthesia provider or PACU nurse. Flow rates and fraction of inspired oxygen (FiO₂) will follow the study protocol (70 liters per minute at 100% O2 for induction of anesthesia, 70 liters per minute at 70% O2 for extubation until 10 minutes after arrival in the PACU with subsequent weaning over the first two hours after PACU arrival).

06

What researchers measure

Primary outcomes

  1. Incidence of perioperative oxygen desaturation

    Incidence of desaturation between induction of anesthesia and discharge from PACU, measured as SpO2 ≤92%

    Time frame: Assessed continuously from induction of anesthesia until discharge from PACU; duration varies depending on surgical procedure and recovery time, up to 24 hours after surgery

Secondary outcomes

  1. End expiratory lung volume (EELV)

    End expiratory lung volume (EELV), measured as difference between pre-oxygenation to post-induction (5min after intubation) and pre-extubation to post-extubation, and pre-extubation to PACU. EELV will be assessed using electrical impedance tomography.

    Time frame: Assessed at predefined perioperative time points from pre-oxygenation until discharge from PACU; duration varies depending on surgical procedure and recovery time, up to 24 hours after surgery.

  2. Time-weighted average of oxygen saturation

    Time-weighted average of peripherally measured oxygen saturation, during induction of anesthesia (until intubation), between extubation and arrival in the PACU, and during PACU stay.

    Time frame: Assessed continuously from induction of anesthesia until discharge from PACU; duration varies depending on surgical procedure and recovery time, up to 24 hours after surgery.

  3. Incidence of postoperative pulmonary complications

    Incidence of postoperative pulmonary complications, defined as re-intubation, emergency non-invasive ventilation, pleural effusion or pneumonia

    Time frame: From induction of anesthesia up to postoperative day 3

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Jul 2029, 33 months after the start.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Nov 12, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2029 → Aug 2029, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 18, 2026
StartActual
Oct 30, 2026was Aug 2026
Primary completionEst.
Jul 30, 2029
CompletionEst.
Aug 3, 2029was Oct 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 12, 2026
Start date
Aug 1, 2026→Oct 30, 2026 (actual)
moved 2 times, Oct 13, 2026 – Nov 12, 2026
Study completion
Oct 31, 2029→Aug 3, 2029
Nov 12, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionIncidence of perioperative oxygen desaturation: how it is measured was reworded
Oct 26, 2026
Contact
No study contact listed any more: removed a•••@bidmc.harvard.edu · •••8056; removed m•••@bidmc.harvard.edu
Nov 12, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Beth Israel Deaconess Medical Center · Boston, United StatesContact removed m•••@bidmc.harvard.edu · •••3216
Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Nov 1, 2026→Oct 30, 2026 (now actual)
    Study completion Oct 31, 2029→Aug 3, 2029
    Contact No study contact listed any more: removed a•••@bidmc.harvard.edu · •••8056; removed m•••@bidmc.harvard.edu
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Beth Israel Deaconess Medical Center · Boston, United StatesContact removed m•••@bidmc.harvard.edu · •••3216
    + 1 other change: verification date
  2. Oct 26, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionIncidence of perioperative oxygen desaturation: how it is measured was reworded
    + 2 other changes: description and arm descriptions
  3. Oct 13, 2026
    Start date Aug 1, 2026→Nov 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07591610
Responsible party
Maximilian S Schaefer (Associate Professor of Anaesthesia, Beth Israel Deaconess Medical Center) — Principal investigator
First posted
May 18, 2026
Start date
Oct 30, 2026
Primary completion
Jul 30, 2029 (estimated)
Completion
Aug 3, 2029 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion